Cancer Advisor

Quick Answer Dr. Thomas Seyfried , a biologist at Boston College, argues that cancer is primarily a mitochondrial metabolic disease rather than a genetic one. His core treatment framework — the Press-Pulse protocol — pairs a therapeutic ketogenic diet that restricts glucose and glutamine (the "press") with pulsed adjuncts like glutaminase-inhibiting drugs, hyperbaric oxygen, or fasting (the "pulse"). Mechanistic and preclinical evidence is strong; human evidence is a mix of promising case reports and small, mostly inconclusive trials — including a 2026 randomized pancreatic cancer trial that showed a survival trend without reaching statistical significance. Most integrative oncologists treat metabolic therapy as a physician-supervised adjunct to, not a replacement for, standard cancer care. In This Guide Who Is Thomas Seyfried? The Case Against Standard-of-Care Statistics Diet and Cancer: Why Food Isn't Neutral Cutting Off Cancer's Fu...

By Editorial Team | Medically reviewed and updated | Last updated: July 2026 | Consolidates and supersedes the six-part Warburg Effect series (June 2026) and "The Warburg Effect Revisited in 2026" (May 2026) Quick Answer The Warburg Effect is the century-old observation that many cancer cells generate energy through aerobic glycolysis — converting glucose to lactate even when oxygen is abundant — rather than relying primarily on mitochondrial oxidative phosphorylation. It is not caused by broken mitochondria, as Otto Warburg originally believed; it is driven by oncogene signaling (KRAS, MYC, HIF-1α, PI3K-AKT-mTOR) that rewires metabolism to supply the building blocks of rapid growth. The strongest Warburg phenotype tends to appear in the most aggressive cancers — pancreatic cancer, glioblastoma, small-cell lung cancer, and triple-negative breast cancer among them — and underlies the entire field of FDG-PET imaging. As of 2026, dozens of drugs and nutraceuticals a...